The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2

Abstract.

Objective: We examined the effects of ML3000 and several non-steroidal antiinflammatory drugs (NSAIDs) on the synthesis of products of 5-LOX (LTB₄, LTC₄) and COX-1/2 (TXB₂, PGE₂) in vitro and ex vivo in order to further elucidate the mechanism of action of ML3000.¶Methods and results: Using a human whole blood assay the effect of ML3000 on the shunt of arachidonic acid to the lipoxygenase pathway when COX is blocked was studied. ML3000 (0.3, 1, 3, 10, 30 μg/ml) and indomethacin (0.3, 1, 3, 10, 30 μg/ml) concentration-dependently inhibited the synthesis of PGE₂ (IC50 = 3.9 and 4.5 μM). In contrast to ML3000, indomethacin produced an increase of LTC₄ of up to 155.5% of control. 5-lipoxygenase inhibition was further tested in a basophilic leukemia cell assay using RBL-1 cells. ML3000 (1-10 μM) inhibited the synthesis of LTB₄ in a concentration related manner (IC₅₀: 3.6 μM). In carrageenan induced rat paw edema, ML3000 and indomethacin completely blocked the formation of PGE₂ in the inflamed tissue. The LTB₄ production in the inflamed paw was reduced to basal levels by ML3000 (10 ± 1.4 pg/paw saline control and 7.5 ± 1.3 - 5.9 ± 3.2 pg/paw ML3000), whereas LTB₄ levels remained markedly elevated as compared to saline control by indomethacin (30.7 pg/paw). 5-LOX inhibition in the inflamed rat colon was investigated by measuring LTB₄ synthesis. MK-886 and ML3000 at 10 mg/kg p.o. reduced LTB4 production to 29.8 ± 4.9 and 30.1 ± 2.8 pg/mg tissue as compared to control (54.2 ± 7.4 mg/kg tissue). LTB₄ levels in the rat stomach were comparable to control (2.5 ± 0.4 pg/ mg protein) after oral administration of ML3000 (10, 30, 100 mg/kg), whereas oral treatment with indomethacin (0.3, 1, 3 mg/kg) or diclofenac (1, 3 mg/kg) increased LTB₄ up to 9.2 ± 2.3 or 8.9 ± 1.6 pg/mg protein. This effect was significant at 1 mg/kg diclofenac and 0.3 mg/kg indomethacin.¶Conclusions: These results provide further evidence, that ML3000 inhibits 5-LOX as well as COX-1 and COX-2 in vitro and in animal experiments. The favourable gastrointestinal (GI) tolerability of the compound is believed to be linked to the mechanism of combined 5-LOX and COX-1/2 inhibition of ML3000.